DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.05 Bil PE Ratio: 47.26 PB Ratio: 15.58 GF Score: 74/100

DexCom Inc at Raymond James Institutional Investors Conference Transcript

Mar 04, 2019 / 08:25PM GMT
Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - Senior Medical Supplies and Devices Analyst

Okay. Super. Welcome to the 40th Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I'm the medical device analyst here. Thank you for joining us and choosing this presentation over the sunshine outside. It's really our pleasure to have with us the senior management team from DexCom, who've been coming to this conference for many years.

So with us, we have the EVP of Strategy and Corporate Development, Steve Pacelli; as well as Sean Christensen, Head of Investor Relations. So with that, I'm going to pass it on to Steve.

Steven R. Pacelli
DexCom, Inc. - EVP of Strategy & Corporate Development

Great. Thank you, Jayson, and thank you all for joining us here this afternoon. So as far as the format, what I thought I would do is I'm going to start with a few highlights from 2018 and a quick review of our guidance for 2019. Then I'm going to take you through kind of a high-level overview of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot